Official announcements
Safety warnings
|
messages in brief
|
21/02/2014
European Medicines Agency recommends restriction of use of Protelos/Osseor
Replacement
|
Medicines
|
04/02/2014
The marketing authorization holder informed its supplied customers by letter dated February 03, 2014 that infusion bags of 0.9% NaCl 500ml Viaflo with Austrian presentation (Ch.No. 13H31E1A) were found in a carton of 0.9% NaCl 500ml Viaflo with…
Replacement
|
Medicines
|
03/02/2014
The marketing authorization holder informed its supplied customers in a letter dated 31.01.2014 that a quality deviation with regard to product- and process-related impurities was found in stability tests for certain batches.
Safety warnings
|
messages in brief
|
03/02/2014
Prescription of CHCs and importance of individual risk factors.
Safety warnings
|
messages in brief
|
24/01/2014
Re-evaluation with regard to higher body weight or BMI
Replacement
|
Medicines
|
23/01/2014
The marketing authorization holder informed its supplied customers in a letter dated 23.01.2014 that the batches listed show deviations in dissolution. The release of the active ingredient amitriptyline after four hours is slightly higher than…
Replacement
|
Medicines
|
30/12/2013
The marketing authorization holder informed its supplied customers in a letter dated December 23, 2013, that it cannot be ruled out that a frequent occurrence of hypersensitivity reactions may occur with this batch and that a precautionary withdrawal…
Safety warnings
|
messages in brief
|
20/12/2013
The preparation Eldisin 5 mg dry ampoules (active ingredient: vindesine sulfate) has been approved in Austria since March 29, 1984. Vindesine is a cytostatic drug from the group of vinca alkaloids and has proven effective primarily in combination…
Recall
|
Medicines
|
19/12/2013
In a letter dated December 19, 2013, the marketing authorization holder informed its customers that an elevated level of a known degradation product of the active ingredient azithromycin has been detected in some vials and that a voluntary recall is…
Replacement
|
Medicines
|
17/12/2013
WABOSAN Arzneimittelvertriebs GmbH has informed its supplied customers by letter dated 12.12.2013 that yellow-orange precipitations have been observed in batch Y260 in individual cases and therefore a precautionary recall is being carried out. This…